Biological markers in breast cancer prognosis and treatment

Journal of B.U.ON.

Volumn 15, Issue 3, 2010, Pages 447-454

  Kesisis, George ^a,c   Kontovinis, L F ^a,c   Gennatas, K ^b   Kortsaris, A H ^c  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Biomarkers; Breast cancer; Predictive; Prognostic

Indexed keywords

BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; MOLECULAR MARKER; MONOCLONAL ANTIBODY; MUCIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; PROTEIN; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; UROKINASE;

ADVANCED CANCER; ANALYTICAL EQUIPMENT; ASSAY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; METASTASIS; METHODOLOGY; MICROARRAY ANALYSIS; ONCOGENE NEU; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SERUM; TREATMENT RESPONSE; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MUCIN-1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 77957738176     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-1674.
2. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-752.
3. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006; 52: 345-351.
4. Klee G, Schreiber WE. MUC1 Gene-Derived Glycoprotein Assays for Monitoring Breast Cancer (CA 15-3, CA 27.29, BR): Are They Measuring the Same Antigen? Arch Pathol Lab Med 2004; 128: 1131-1135.
5. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-1466.
6. Ebeling FG, Stieber P, Untch M et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002; 86: 1217-1222.
7. Gion M, Boracchi P, Dittadi R et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers: An old player for a new game. Eur J Cancer 2002; 38: 1181-1188. (Pubitemid 34603477)
8. Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002; 76: 95-102.
9. National Cancer Institute. Cancer Facts, Fact Sheet 5.18 (1998), 1-5.
10. Rojas MP, Telaro E, Russo A et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2005 Jan 25; (1): CD001768.
11. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439.
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
13. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 protein is released from tumour cells by proteolytic cleavage. Oncogene 1993; 3: 2917-2923. (Pubitemid 23312894)
14. Garoufali A, Kyriakou F, Kountourakis P et al. Extracellular domain of HER2: A useful marker for the initial workup and follow up of HER2-positive breast cancer. J BUON 2008; 13: 409-413.
15. Baskic D, Ristic P, Pavlovic S, Arsenijevic N. Serum HER2 and CA 15-3 in breast cancer patients. J BUON 2004; 9: 289-294.
16. Hayes DF, Yamauchi H, Broadwater G et al. Circulating HER-2 extracellular domain (ECD/HER-2) as a prognostic factor in patients with metastatic breast cancer: Cancer & Leukemia Group B study 8862. Clin Cancer Res 2001; 7: 2703-2711.
17. Baselga J. Is Circulating HER-2 More Than Just a Tumor Marker? Clin Cancer Res 2001; 7: 2605-2607.
18. Hudis CA. Trastuzumab-Mechanism of Action and Use in Clinical Practice. N Engl J Med 2007; 357: 39-51.
19. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749. (Pubitemid 32691885)
20. Carney WP, Neumann R Lipton A, et al. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003; 49: 1579-1598.
21. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
22. Bloom HJ. Prognosis in carcinoma of the breast. Br J Cancer 1950; 4: 259-288.
23. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
24. Williams MR, Hinton CP, Todd JH, Morgan DA, Elston CW, Blarney RW. The prediction of local or regional recurrence after simple mastectomy for operable breast cancer. Br J Surgery 1985; 72: 721-723.
25. Todd JH, Dowle C, Williams MR et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987; 56: 489-492. (Pubitemid 17146357)
26. www.adjuvantonline.com
27. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.
28. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23: 2716-2725.
29. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-616. (Pubitemid 34498648)
30. Bezwoda WR, Esser JD, Dansey R et al. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991; 68: 867-872.
31. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978; 103: 1742-1751.
32. Ravdin PM, Green S, Dorr TM et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992; 10: 1284-1291.
33. Bardou VJ, Arpino G, Elledge RM et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003; 21: 1973-1979.
34. Grann VR, Troxel AB, Zojwalla NJ et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005; 103: 2241-2251. (Pubitemid 40686567)
35. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365 (9472): 1687-1717.
36. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
37. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity oftargeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
38. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-1655.
39. Slamon DJ, Clark GM, Wong SM et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 177-182.
40. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356. (Pubitemid 32366985)
41. Joensuu H, Kellokumpu-Lehtinen PI, Bono P et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. N Engl J Med 2006; 354: 809-820. (Pubitemid 43290919)
42. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-7490. (Pubitemid 46291811)
43. O'Malley FP, Chia S, Tu D et al. Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). J Clin Oncol 2006; 24 (Suppl 18S): 533.
44. Press MF, Sauter G, Buyse M et al. Alteration of topoisomerase II-alpha gene in human breast cancer and its association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2007; 25 (Suppl 18S): 524.
45. Stephens RW, Brunner N, Janicke F et al. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998; 52: 99-111. (Pubitemid 29056088)
46. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence studies. Clin Chem 2002; 48: 1194-1197. (Pubitemid 34809824)
47. Look MP, van Putten WL, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-128.
48. Janicke F, Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-920.
49. Paik S, Shak S, Tang G et al. A mutagene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
50. Albain K, Barlow W, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). Presented at 30th Annual San Antonio Breast Cancer Symposium; 2007; Abstract 10; San Antonio, TX.
51. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 2006; 24: 3726-3734.
52. Goldstein LJ, Gray R, Badve S et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26: 4063-4071.
53. Dowsett M, Cuzick J, Wales C et al. Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Presented at 31st Annual San Antonio Breast Cancer Symposium; 2008; Abstract 53; San Antonio, TX.
54. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
55. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
56. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
57. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679. (Pubitemid 40260888)
58. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988. (Pubitemid 36418143)
59. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226. (Pubitemid 46143225)
60. Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005; 102: 3738-3743.
61. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560-569. (Pubitemid 44200649)
62. Ein-Dor L, Kela I, Getz G et al. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 2005; 21: 171-178.
63. Chang JC, Wooten EC, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.
64. Jansen MP, Foekens JA, van Staveren IL et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23: 732-740.
65. Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607-616. (Pubitemid 38748922)
66. Leong CO, Vidnovic N, DeYoung MP et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-1380. (Pubitemid 46718425)
67. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96-108.
68. Ring BZ, Seitz RS, Beck R et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast. J Clin Oncol 2006; 24: 3039-3047. (Pubitemid 46638938)